Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 11/20 | 0.60 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | PI4KA | P42356 | 1/20 | 0.50 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.50 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14472999 | 1.00 | AHCY (0.60) | AHCYADORA2AADORA1ALDH1A1PI4KA | |
| SCHEMBL14139510 | 0.91 | AHCY (0.56) | AHCYADORA2AADORA1ALDH1A1PI4KA | |
| SCHEMBL14379019 | 0.89 | ADORA2A (0.60) | AHCYADORA2AADORA1ALDH1A1PI4KA | |
| SCHEMBL14472882 | 0.88 | AHCY (0.56) | AHCYADORA2AADORA1ALDH1A1PI4KA | |
| SCHEMBL15606513 | 0.86 | ADORA2A (0.57) | AHCYADORA2AADORA1ALDH1A1PI4KA | |
| SCHEMBL91112 | 0.85 | FDPS (0.48) | AHCYADORA2AADORA1ALDH1A1 | |
| SCHEMBL30292318 | 0.84 | ADORA2A (0.64) | AHCYADORA2AADORA1ALDH1A1PI4KA | |
| SCHEMBL4093935 | 0.84 | ADORA2A (0.64) | AHCYADORA2AADORA1ALDH1A1PI4KA | |
| SCHEMBL10642386 | 0.84 | CCNE1 (0.51) | AHCYADORA2AADORA1ALDH1A1 | |
| SCHEMBL13625720 | 0.82 | BLM (0.45) | AHCYADORA2AADORA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283369-B2 | Compounds and compositions and methods of use | ARDEA BIOSCIENCES. INC. (US) | 2012-10-09 | — | — | US | disclosed |
| US-8173690-B2 | Compounds, compositions and methods of using same for modulating uric acid levels | ARDEA BIOSCIENCES, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-20110268801-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20100286084-A1 | Oligomer-Nucleoside Phosphate Conjugates | NEKTAR THERAPEUTICS (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100056464-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | ARDEA BIOSCIENCES (US) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110268801-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | AHCY 493/4885ADORA2A 306/4885ADORA1 916/4885 |
| US-20100286084-A1 | Oligomer-Nucleoside Phosphate Conjugates | ENTPD5, SLC29A2, SLC29A1 | AHCY 1481/4885ADORA2A 93/4885ADORA1 115/4885 |
| US-20100056464-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | XDH, PON1, OAT | AHCY 99/4885ADORA2A 211/4885ADORA1 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.